Kunming Biomed International (KBI)

💡 What are the most important endpoints to consider when designing a preclinical efficacy trial, in non-human primates (#NHP), for Parkinson's disease (#PD) and Alzheimer's disease (#AD) drug development programs? KBI recently received much attention and enthusiasm from attendees for the technical platforms they presented at the #SfN-2024 conference in Chicago, IL. The attached poster highlights how KBI has addressed the question above, by focusing on 4 core components to produce results aimed at evaluating the performance of a therapeutic candidate: 1. Behavior, to provide functional readouts; 2. PET and MRI imaging, to show target engagement or disease modification; 3. In-life biomarker evaluation to monitor model progression, ensure candidate performance and potentially discover a surrogate to central activity in easily obtained in biofluids (i.e. CSF, plasma, urine, exosomes). 4. Post-mortem assessments, to show modification to degenerative outcomes within the anatomy of the #CNS.   Providing the technical platforms as described herein is based on the necessity for NHP use in development of therapies for neurodegenerative disease. Firstly, to engage with neuro-based targets in a system more aligned with the complex CNS of a human and secondly to potentially de-risk or optimize clinical trial design using a species with behavior and imaging platforms used in human evaluations. KBI is committed to ethically researching and optimizing disease models towards these ends. We invite you to view the attached poster showcasing our technical platforms developed for CNS-focused NHP studies. For more insights into our disease models and technical platforms or to discover how KBI can support your research, please feel free to contact us at bd@kbimed.com. #CRO

💡 "How many NASH monkeys does #KBI currently have?" 🎤 "How long does a typical #NHP NASH study last?" 🔍 "What is #KBI's success rate for liver biopsy studies?"   Are these questions also aligned with your interests as you focus your energy on MASH drug development?   It's been about two weeks since KBI's presentation at the #MASH2024 conference in Boston, yet the dialogue between KBI and MASH drug researchers continues to thrive. Researchers have raised various questions about using the nonhuman primate (NHP) MASH model for #preclinical research on new drugs, and KBI's MASH science team has provided valuable insights.   If you missed our presentation, don't worry! We'll be sharing the poster presented at the conference right here. KBI looks forward to engaging in an in-depth discussion about MASH preclinical research with you, as we value your excellent insights! For further discussion, please feel free to contact us at bd@kbimed.com.   #CRO #Obesity #IND 

As the 2024 MASH Drug Development Summit goes on, we are excited to share that Dr. Lichuan Yang has captivated audiences with his enlightening presentation, "Non-Human Primate Obese Models for Preclinical Pharmacology Research." Don’t worry if you missed the chance, the conversation continues, and our team is still here to meet you on site.   The Summit is far from reaching its end, and we are looking forward to your arrival with great enthusiasm. Let's bring this event to a successful and memorable close together! #CRO #MASH #NHP #DiseaseModel #Metabolism #obesity

The countdown is on! Just one day remains until the MASH Drug Development Summit 2024! We are excited to announce that Our CEO, Dr. Lichuan Yang, a pioneer in NHP research, will deliver his presentation titled "Nonhuman Primate Obese Models for Preclinical Pharmacology Research" at 11:40 AM on September 25th. Mark your calendars and don't miss this exceptional opportunity to gain some valuable insights and ideas about non-human primates (NHP) metabolic disease model. We're eagerly anticipating your presence at the summit! If you're seeking a more in-depth discussion and exploring collaborative opportunities, please feel free to reach out to Chen (Angela) Xu or Quanqing (Alex) Han Han on LinkedIn for more details or to schedule a further discussion. Don't let this opportunity slip away - join us at the MASH Drug Development Summit 2024 for an enlightening and engaging experience. See you there! #CRO  #MASH  #NHP  #DiseaseModel  #Metabolism  #obesity

Join us from October 5th to 9th in Chicago, USA @ Neuroscience 2024 (SfN24)! We’re thrilled to announce that Dr. Lichuan Yang, KBI’s CEO, Dr. Lichuan Yang, will be presenting at the summit. Be sure to check out our KBI’s poster titled: “A technical platform solution to develop, characterize and implement macaque models of neurodegenerative disease”.   Don’t miss Dr Yang’s insights on KBI’s latest advancements in NHP CNS disease models, including:   1. Extensive aging NHP disease animal cohort – your potential key to clinical trial success. 2. Reliable and trustful models for neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). 3. Effective assessment methods for in-life and post-mortem stages. 4. Advanced imaging and behavioral analyses platforms.   We warmly invite you to visit our Posterboard (LBA82) at Neuroscience 2024. Let’s discuss new insights and collaborate on your research!   For inquiries or to schedule a meeting, please connect with Quanqing (Alex) Han or Chen (Angela) Xu on LinkedIn.   We can’t wait to see you at the summit in Chicago!   #SfN24 #CRO #CNS #NHP #DiseaseModel #PD #AD

The 8th MASH Drug Development Summit 2024 is just two weeks away!   We’re thrilled to announce that KBI’s CEO, Dr. Lichuan Yang, a leading expert in non-human primate (NHP) research, will present on "Nonhuman Primate Obese Models for Preclinical Pharmacology Research" at the Summit. Dr. Yang will showcase KBI’s latest advancements and achievements in NHP disease models, including: 1. The features of spontaneous and high fat diet induced obese monkey models. 2. New biochemistry and imaging technologies for validating obesity model and evaluating treatment efficacy. 3. Efficacy studies with various substances on KBI’s obese monkey models.   We would like to extend a cordial invitation for you to visit our Booth at MASH 2024 Summit in Boston for an in-depth discussion and cutting-edge insights into your drug development and research.   For any interests or inquiries, or to schedule a meeting, connect with Quanqing (Alex) Han (on-site) or Chen (Angela) Xu (on-line) on LinkedIn.   We look forward to meeting you at the summit. #CRO #MASH #NHP #DiseaseModel #Metabolism #obesity

In the previous article, we explored the potential of targeting INHBE for lipid-lowering and briefly introduced Kunming Biomed International (KBI)'s strengths in pursuing projects focusing on such targets, which garnered significant attention from professionals in drug development. In this article, we will provide a detailed overview of how KBI can support drug preclinical research related to these targets. #CRO #INHBE #Obesity #NHP #DiseaseModel

Recent research has spotlighted Inhibin βE (INHBE) as a promising target in fat reduction therapies using small interfering RNA (siRNA) therapeutics. In the dynamic field of INHBE-related research, KBI is poised to support the advancement of siRNA therapies targeting INHBE through a strategic "combination punch". We invite you to engage with us and share our insights on preclinical research surrounding the INHBE target. If you have unique insights into INHBE or would like to conduct related experiments on NHP, please feel free to contact us at bd@kbimed.com. #INHBE #CRO #NHP #Preclinical #DiseaseModel #KBI

July is Dry Eye Awareness Month! Aimed at raising awareness for the prevention and treatment of dry eye disease. With the increasing use of electronic devices and the aging population, the incidence of ophthalmic diseases is rising, with a significant number of dry eye disease patients. This may be related to the general lack of awareness about preventing dry eye disease. In early 2023, one popular Chinese TV series "The Knockout" highlighted Gao Qiqiang’s battle with dry eye disease, shedding light on its impact. Although dry eye disease doesn't sound as frightening as a "fatal disease," it negatively impacts patients' quality of life and can even lead to permanent vision damage, which should not be underestimated. At KBI, a leading CRO in ophthalmology, we are dedicated to combating dry eye disease through NHP models. Since 2019, we have been screening our large population of aged cynomolgus monkeys to identify spontaneous models for dry eye disease and developed a comprehensive platform for its diagnosis and evaluation, to support drug development efforts. KBI's mission and goal, is to raise awareness, enhance treatment, and prevent vision loss. Together with our global sponsors and partners, we strive to keep dry eye disease from affecting lives. Let's prioritize eye health and spread awareness this Dry Eye Awareness Month!. Contact us at bd@kbimed.com, to find more about NHP dry eye disease models. #Dryeye #NHP #CRO #KBI #DiseaseModel #DrugEfficacy

The 84th Scientific Sessions of the American Diabetes Association have come to a close, marking an occasion of great honor for us as we had the privilege of presenting two posters at this esteemed gathering. 🔬 Comparative Efficacy of Irbesartan and Sotagliflozin in a Nonhuman Primate (NHP) Model of Diabetic Kidney Disease 🔬 Nonhuman Primate Obesity Model for the Translation of Target-Based Precision Medicine Our posters underscored the significance of our non-human primate (NHP) disease models and the research platform developed by KBI. They featured insights into our work with models of obesity and diabetic nephropathy. These models stand out for their high clinical translational relevance, allowing for effective evaluations of various drugs and treatments. This capability significantly enhances the preclinical phase of drug development and research. For further details regarding the posters, please contact us at marketing@kbimed.com. #ADASciSession #NHP #CRO #KBI #Diabetes #DiseaseModel